Related Experiment Videos
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors
Jacques B de Kok1, Gerald W Verhaegh, Rian W Roelofs
1Department of Clinical Chemistry, University Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands.
Cancer Research
|May 1, 2002
Summary
Prostate cancer gene DD3(PCA3) shows high sensitivity and specificity for detecting prostate tumor cells. DD3(PCA3) measurements may be clinically useful in biopsies or bodily fluids for prostate cancer diagnosis.
Area of Science:
- Molecular Biology
- Oncology
- Biomarker Discovery
Background:
- DD3(PCA3) is a highly prostate cancer-specific gene.
- Accurate quantification methods are needed for its diagnostic and prognostic potential.
- Comparison with other markers like hTERT is valuable.
Purpose of the Study:
- To develop a method for accurate quantification of DD3(PCA3) mRNA.
- To evaluate the diagnostic and prognostic value of DD3(PCA3) in prostate tissues.
- To compare DD3(PCA3) efficacy with hTERT for prostate cancer detection.
Main Methods:
- Real-time quantitative reverse transcription-PCR for DD3(PCA3) mRNA quantification.
- Assessment of gene expression in normal prostate, other tissues, and prostate tumors.
- Calculation of sensitivity and specificity using Area Under the Receiver Operating Characteristic Curve (AUC-ROC).
Main Results:
- DD3(PCA3) showed high specificity, with low expression in normal prostate and absence in other tissues.
- DD3(PCA3) demonstrated superior diagnostic efficacy (AUC-ROC, 0.98) compared to hTERT (AUC-ROC, 0.88).
- Tumor tissues exhibited a significantly higher mRNA expression increase for DD3(PCA3) (34-fold) than hTERT (6-fold).
Conclusions:
- DD3(PCA3) gene expression is a highly sensitive and specific marker for detecting prostate tumor cells.
- DD3(PCA3) measurements offer clinical utility in prostate needle biopsies and bodily fluids.
- DD3(PCA3) shows greater diagnostic potential than hTERT for prostate cancer.